Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
Novartis
Novartis
Kivu Bioscience Inc.
Hoffmann-La Roche
Endeavor Biomedicines, Inc.
ViroMissile, Inc.
AstraZeneca
MacroGenics
Adela, Inc
Perspective Therapeutics
Ocellaris Pharma, Inc.
Eli Lilly and Company
Var2 Pharmaceuticals
Tanabe Pharma America, Inc.
Transgene
HiFiBiO Therapeutics
TScan Therapeutics, Inc.
Tango Therapeutics, Inc.
Tango Therapeutics, Inc.
Bayer
Actym Therapeutics, Inc.
Valo Therapeutics Oy
Epkin
Guangzhou FineImmune Biotechnology Co., LTD.
Turning Point Therapeutics, Inc.
Telix Pharmaceuticals (Innovations) Pty Limited
PharmaMar
Hutchmed
Elevation Oncology
Labcorp Corporation of America Holdings, Inc
Intensity Therapeutics, Inc.
Ipsen
BostonGene
Cybrexa Therapeutics
Agenus Inc.
Cyteir Therapeutics, Inc.
Actuate Therapeutics Inc.
NantCell, Inc.
Xencor, Inc.
Prelude Therapeutics
Innolake Biopharm
TransThera Sciences (Nanjing), Inc.
Pfizer
Ipsen
Adaptimmune
Corvus Pharmaceuticals, Inc.
Deciphera Pharmaceuticals, LLC
Prelude Therapeutics
Sumitomo Pharma America, Inc.
pharmaand GmbH
Hoffmann-La Roche